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Abstract
Background
Multimorbidity is a global health challenge that is associated with polypharmacy, increasing
the risk of potentially inappropriate prescribing (PIP). There are tools to improve prescrip-
tion, such as implicit and explicit criteria.
Objective
To estimate the prevalence of PIP in a population aged 65 to 74 years with multimorbidity
and polypharmacy, according to American Geriatrics Society Beers Criteria® (2015, 2019),
the Screening Tool of Older Person’s Prescription -STOPP- criteria (2008, 2014), and the
Medication Appropriateness Index -MAI- criteria in primary care.
Methods
This was an observational, descriptive, cross-sectional study. The sample included 593
community-dwelling elderly aged 65 to 74 years, with multimorbidity and polypharmacy,
who participated in the MULTIPAP trial. Socio-demographic, clinical, professional, and
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pharmacological-treatment variables were recorded. Potentially inappropriate prescribing
was detected by computerized prescription assistance system, and family doctors evalu-
ated the MAI. The MAI-associated factors were analysed using a logistic regression model.
Results
A total of 4,386 prescriptions were evaluated. The mean number of drugs was 7.4 (2.4 SD).
A total of 94.1% of the patients in the study had at least one criterion for drug inappropriate-
ness according to the MAI. Potentially inappropriate prescribing was detected in 57.7%,
43.6%, 68.8% and 71% of 50 patients according to the explicit criteria STOPP 2014, STOPP
2008, Beers 2019 and Beers 2015 respectively. For every new drug taken by a patient, the
MAI score increased by 2.41 (95% CI 1.46; 3.35) points. Diabetes, ischaemic heart disease
and asthma were independently associated with lower summated MAI scores.
Conclusions
The prevalence of potentially inappropriate prescribing detected in the sample was high and
in agreement with previous literature for populations with multimorbidity and polypharmacy.
The MAI criteria detected greater inappropriateness than did the explicit criteria, but their
application was more complex and difficult to automate.
Introduction
Multimorbidity, defined by the WHO as the coexistence of two or more chronic illnesses in a
person [1], is a growing phenomenon. It describes the complex interaction in a patient of sev-
eral co-existing diseases. It has become a health problem and an international health challenge
[2] resulting from increased life expectancy and non-transmittable disease rates, among other
factors.
Patients with multimorbidity usually present polypharmacy, defined as the simultaneous
use of several medicines[3]. Data from the USA National Health Survey yielded a prevalence
of polypharmacy of 39% in the population aged over 65 years [4]. An European study, with
medication dispensing data for 310,000 adults, observed that the proportion of patients with
�5 drugs dispensed doubled, reaching 20.8% in the 1995–2014 period[5]. In the National
Health Survey in Spain in 2017, in this same age range, 27.7% of respondents reported con-
suming at least 5 or more drugs or pharmaceutical preparations [6].
Polypharmacy entails a greater risk for potentially inappropriate prescribing (PIP), which is
defined as “the prescribing of medications that should generally be avoided in persons 65 years
or older because they are either ineffective or they pose unnecessarily high risk where a safer
alternative is available” [7]. Optimization and the appropriateness of prescriptions in this pop-
ulation has become a global public health problem.
To analyse potentially inappropriate prescriptions in primary care complex patients,
explicit and implicit methods have been proposed [8,9]. Explicit methods, are focused on
drugs (e.g., Beers and STOPP/START criteria), measuring how they fit to a set of predefined
criteria [10–12]. These criteria are updated according to the available evidence for each differ-
ent drug catalogues (USA or Europe). The implicit criteria are based on the global assessment
by a health professional (pharmacist, internist, geriatrician or primary care physician), which
takes into account the overall situation of the patient and whether the prescription
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corresponds to an indication or need. The most accepted implicit method internationally is
the medication appropriateness index (MAI) [13].
Depending in the criteria used, the prevalence of patients with PIP differs significantly
depending on the tools and the populations analysed (hospitalized, institutionalized or com-
munity patients) [14,15]. It ranges from 40.4% detected using STOPP criteria [16] to 98.7% of
prevalence using MAI criteria in primary care young elderly patients taking at least 5 drugs
[17]. In Spain, the MAI has been evaluated in hospitalised patients [18] and has also been
adapted and validated for primary care [19]. However, we still lack in young-elderly popula-
tion studies in primary care patients complaining with multimorbidity and polypharmacy.
The association between explicit methods (STOPP or Beers) and implicit methods (MAI)
in the primary care population has been investigated [20]. Recently, a study was published
comparing the sensitivity and specificity of these three methods performed by two pharma-
cists, using the MAI as the gold standard, in a population from Kuwait. This study compared
Beers 2015, STOPP 2014 and FORTA with the MAI, obtaining kappa values of 0.16 (p
<0.001), 0.40 (p<0.001) and 0.23 (p<0.001), respectively [21]. The most updated version of
Beers 2019 has not been compared with the rest of the criteria.
Studies have shown association of high prevalence of PIP with worse health outcomes in
patients such as unscheduled outpatient visits, emergency room visits, adverse events [17,22–
24], and hospital admissions and re-admissions [25–28]. Furthermore, this association has
also been found when analysing patient reported outcomes (PROMs), such as quality of life
(EQ-5D-3L) [29].
In an attempt to facilitate the detection of PIP in patients, in recent years, explicit criteria
(STOPP and Beers) have been automated into computerized prescription assistance systems
(CPAS) [30]. The translation of explicit criteria to computer algorithms is complex [31,32]
although easier than programming the implicit criteria (MAI) to computer pre-sets. The MAI
criteria imply evaluating ten different aspects of each drug including indication, dose, effec-
tiveness, interactions and duration, among others. Some of this evaluations even require health
professional confirmation making this implicit criteria time consuming [13,33–35].
The main aim of this study was to estimate the prevalence of PIP in a population aged 65 to
74 years with multimorbidity and polypharmacy, according to explicit criteria (Beers 2015 and
2019, STOPP 2008 and 2014); and implicit criteria (Medication appropriateness index–MAI-)
in primary care. The secondary objectives were to assess the clinical and socio-demographic
predictors for PIP and to compare these criteria in order to detect PIP with greater applicabil-
ity to the Spanish population.
Material and methods
The project has been favourably evaluated by the Central Committee of Primary Care Research
of the Community of Madrid, the Commission for Health Research of the Aragon Institute for
Health Research (IIS Aragon), and the Commission for Health Research of the Bio-Sanitary
Research Institute in Malaga (IBIMA). The trial protocol was approved by the Clinical
Research Ethics Committee of Aragon (CEICA) on September 30, 2015 (CP14/2015), and by
the Research Ethics Committee of the Province of Malaga on September 25, 2015. Participant
provided written consent to participate in the Multi-PAP trial Clinicaltrials.gov
NCT02866799.
Design
This was a cross-sectional, descriptive, multicentric, observational study conducted in the
Spanish primary care setting.
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Participants and setting
Patients aged 65 to 74 years with multimorbidity (� 3 diseases) and polypharmacy (� 5 pre-
scriptions taken for at least 3 months), who had attended their doctor consultation at least
once over the last year and provided written consent to participate in the Multi-PAP trial Clin-
icaltrials.gov NCT02866799 were included [36]. Institutionalized patients, those whose life
expectancy was <12 months, as estimated by their doctor, and patients with any severe mental
disorder were excluded. For physicians, the inclusion criterion was at least one year in their
job. Presentations of the Multi-PAP project were held in health centres, and professionals were
offered the chance to participate. One hundred and seventeen family doctors from 38 health-
care centres from three Spanish regions (Andalucia, Aragon, and Madrid) and 593 patients
agreed to participate. For the proposed objective and based on previous studies in a similar
population reporting an average MAI summated score of 15.8 (10.1 SD) [17], with this sample
size and a design effect of 1.2, a maximum type I error of 0.975% with a 95% confidence inter-
val (95%CI) was determined.
Data collection
Sociodemographic and clinical data were obtained during the period of patient recruitment in
the MULTIPAP study, which was conducted between December 2016 and January 2017
through an interview with each patient’s family doctor.
The method of collecting data on patients and doctors was not the same. Data on profes-
sionals (age, sex, length of physician career, and being postgraduate medical supervisor) were
recorded by each physician in the data collection notebook after signing their commitment to
collaborate in the study. Subsequently, sociodemographic and clinical data on patients were
collected through an interview with each patient’s general practitioner after signing the written
informed consent.
Subsequently, the data were uploaded from the DCN into the CPAS ChecktheMeds1.
Variables
The following socio-demographic variables were recorded for patients: age, sex, marital status,
education level, social class according to the Spanish classification [37], and family income in
thousands of euros adjusted by the number of people in the household (using the method pro-
posed by the OECD Organisation for Economic Co-operation and Development). Addition-
ally, the following clinical variables were collected: number of active pharmaceutical
ingredients per patient according to the Anatomical, Therapeutic, Chemical (ATC) classifica-
tion system; and chronic conditions in accordance with the international classification of pri-
mary care (ICPC), with the most relevant ones selected according to the criterion by
O’Halloran [38]. The variables for the professional were age, sex, length of physician career,
and being postgraduate medical supervisor.
Evaluation of prescribing appropriateness
One researcher with broad clinical and therapeutic drug monitoring expertise supervised
information transfer to the ChecktheMeds1 tool and used this tool to globally review the treat-
ment of all patients. ChecktheMeds1 is a web-based tool to help health professionals for treat-
ment plan review. It quickly analyses potentially inappropriate prescriptions, potentially drug-
drug and drug-disease interactions, contraindications and adverse events. It takes into account
clinical variables, diagnosis codes and the whole treatment of a patient. All collected data were
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supervised by a second reviewer. PIP was identified using the four explicit criteria selected and
using one implicit criterion.
The explicit criteria were a) the 2019 Updated Beers criteria by the American Geriatric Soci-
ety [11], b) the 2015 Beers criteria by the American Geriatrics Society [39], c) the 2014 v2
STOPP criteria [12], and d) the 2008 v1 STOPP criteria [40]. All the STOPP and Beers criteria
were analysed. In agreement with former studies and to avoid potential information bias, this
research team agreed on omitting the A1P STOPP criterion from the analysis (any drug pre-
scribed but not indicated by clinical evidence) to prevent its overestimation [41]. START crite-
ria assessing potential prescribing omissions were dismissed because the focus of this study
was on already-prescribed inappropriate medications, instead of the need of starting new med-
ications. The four criteria were automatically reported by the CPAS and compared.
The implicit criterion was the MAI [13], which includes 10 implicit criteria (indication,
effectiveness, dosage, correct directions, practical directions, drug-drug interactions, drug-dis-
ease interaction, duplication, duration and expense). The MAI measures the suitability of each
of a patient’s drugs to these 10 criteria on a 3-grade Likert scale (A appropriate, C inappropri-
ate). Only the “correct direction” criterion was omitted because this information was not able
to be evaluated.
Each medication prescribed was rated by an independent family physician with pharmaco-
logical expertise for each Region, applying the usual weighted criteria (three raters in total).
The raters were able to review the clinical history of the patients in the study to obtain as much
information as possible. The drug-drug and drug-disease interactions were detected with the
help of the CPAS ChecktheMeds1. A pilot rating of 17 different drugs (three patients) was car-
ried out between the three raters using the same electronic health records and cases. Discrep-
ancies were discussed until a consensus was reached. Additionally, a family physician and a
pharmacist conducted a second appraisal of the inter-observer reliability over a randomly
selected 10% of the completed questionnaires.
The MAI was evaluated by drug and by patient. The following were calculated: the percent-
age of drugs with at least one inappropriate criterion; the percentage of patients with at least
one inappropriate criterion for any of the drugs [13]; the percentage of patients with a sum-
mated MAI of 3 or more [20]; and the summated MAI score per drug and per patient.
Statistical analysis
Categorical variables are presented as frequencies and percentages. Quantitative variables are
presented as the mean and standard deviation, with the corresponding CI 95% when the data
fit a normal distribution or by the median and interquartile range (IQR) in the case of asym-
metric data distribution. The MAI was used a reference point due to it’s reliably and validity as
a standardized assessment tool. For the gold standard test (MAI), a pilot rating for the level of
absolute agreement across the three raters was evaluated using the intraclass correlation coeffi-
cient (ICC). Specificity and sensitivity of the explicit criteria were assessed using a contingency
table, and confidence intervals were calculated using exact correction. Concordance between
implicit and explicit criteria was estimated using kappa statistics. A multivariate linear regres-
sion model was developed to assess factors associated with the summated MAI score per
patient (maximum of 18 points multiplied by each drug prescribed). The independent vari-
ables were those reaching statistical significance in the univariate analysis or considered of
clinical relevance. Five different multivariate logistic regression models were built to deter-
mined factors that were independently associated with PIP, with robust estimators that con-
trolled for the effect of cluster sampling. For each model, the dependent variable was
constructed as follows: (I) being prescribed at least one PIP according to Beers 2019 criteria
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(0 = no, 1 = yes); (II) being prescribed at least one PIP according to Beers 2015 criteria (0 = no,
1 = yes); (III) being prescribed at least one PIP according to STOPP 2014 criteria (0 = no,
1 = yes); (IV) being prescribed at least one PIP according to STOPP 2008 criteria (0 = no,
1 = yes); and (V) being prescribed medication with one or more inappropriate rating in the
MAI criteria (0 = summated patient score 0, 1 = summated patient score�1) according to the
original Hanlon definition [13]. Stata v14.0 software was employed for the statistical analyses.
Ethical approval
The MULTIPAP study was designed in accordance with the basic ethical principles of auton-
omy, beneficence, justice, and non-maleficence and was conducted in accordance with the
rules of Good Clinical Practice outlined in the most recent Declaration of Helsinki and the
Oviedo Convention (1997). Written informed consent of patients was required. Data confi-
dentiality and anonymity was ensured, according to the provisions of Spanish Law 15/1999,
both during the implementation phase of the project and in any resulting presentations or
publications. The project has been favourably evaluated by the Central Committee of Primary
Care Research of the Community of Madrid, the Commission for Health Research of the Ara-
gon Institute for Health Research (IIS Aragon), and the Commission for Health Research of
the Bio-Sanitary Research Institute in Malaga (IBIMA). It was approved by the Clinical
Research Ethics Committee of Aragon (CEICA) on September 30, 2015, and by the Research
Ethics Committee of the Province of Malaga on September 25, 2015.
Results
Characteristics of the study participants
A total of 4,386 prescriptions were rated for the 593 included patients. The mean age of the
patients was 69.7 (2.7 SD) years, the age range was 65–74, 55.8% were women, 75.4% were
married, and 17.9% lived alone. Table 1 provides the main socio-demographic and clinical
characteristics of the patients and the professionals variables. Among chronic clinical condi-
tions, 78.9% of patients had hypertension, and 50.8% hypercholesterolemia. The mean number
of chronic conditions and medications per patient were 5.8 (2.3 SD) diseases and 7.4 (2.4 SD)
prescriptions per patient. 17.9% of patients were prescribed�10 drugs (Table 1).
For ATC groups, one of every three drugs (34.1%) prescribed belonged to the cardiovascu-
lar group, followed by metabolism and alimentary tract group and nervous system group.
Table 2 shows the categories of drugs prescribed to patients according to ATC classification.
Inappropriate prescribing ratings
The implicit criteria, the MAI, was evaluated for 4,386 prescriptions (589 patients). Four
patients could not be evaluated due to not being able to access their medical records at the
time of the evaluation. Moderate absolute agreement between the three raters was found, with
an intraclass correlation coefficient of 0.41 (CI 95% 0.109–0.701). More than half of the pre-
scriptions were considered appropriate (51.9%). The mean summated MAI score per drug was
1.4 (2.3 SD) (median 0; IQR 0–1). The mean summated MAI score per patient was 17.5 (16.8
SD) (median 14, IQR 5–25; range 0–102). Five hundred and fifty-four patients out of 589 had
one or more inappropriate rating among their prescribed medications (94.1%). Of the 2,110
drugs considered inappropriate, 1,416 (67.1%) had less than three MAI inappropriate criteria
ratings according to the Steinman classification [20], and 694 (32.9) met three or more MAI
inappropriate criteria ratings. The MAI criteria with the highest inappropriate percentages
were cost-effectiveness, duration, effectiveness and potential drug-drug interactions. Table 3
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Table 1. Socio-demographic, clinical, and pharmacological characteristics of patients and physicians
characteristic.
Patient Characteristics (N = 593)
Age, M (SD) 69.7 (2.7)
Gender, n (%)
Female 331 (55.8)
Male 262 (44.2)
Nationality, n (%)
Spanish 583 (98.3)
Other 10 (1.7)
Marital status, n (%)
Single, divorced, widow 146 (24.6)
Married, living with couple 447 (75.4)
Living alone, n (%) 106 (17.9)
Educational level, n (%)
Primary education not completed 279 (47.0)
Primary education 196 (33.1)
Secondary and superior education 118 (19.9)
Social class according to occupation, n (%)
Supervisors, managers, and directors 234 (39.5)
Skilled primary sector 217 (36.6)
Unskilled 142 (23.9)
Patient Clinical Conditions
Number of chronic illnesses�, median (IQR) 5.0 (4.0, 7.0)
Most frequent chronic conditions, n (%, 95% CI)
High blood pressure 468 (78.9; 75.6–82.2)
Dyslipidemia 301 (50.8; 46.7–54.8)
Diabetes 250 (43.3; 38.1–46.1)
Osteoarthritis (knee, hand, hip and other) 225 (37.9; 34.0–41.9)
Anxiety/Depression 176 (29.7; 26.0–33.4)
Hypothyroidism 113 (19.1; 15.9–22.2)
Obesity 103 (17.4; 14.3–20.4)
Benign Prostatic Hyperplasia (% over Men) 87 (33.2; 27.5–38.9)
Ischemic heart disease 101 (17.0; 14.0–20.1)
Chronic heart failure 21 (3.5; 2.0–5.0)
Asthma 53 (8.9; 6.6–11.2)
Chronic Obstructive Pulmonary Disease 64 (10.8; 8.3–13.3)
Osteoporosis 75 (12.6; 10.0–15.3)
Atrial Fibrillation/Flutter 73 (12.3; 9.7–15.0)
Esophageal diseases/peptic ulcers 50 (8.4; 6.2–10.7)s
Number of drugs, median (IQR) 7.0 (6.0, 9.0)
5–6 drugs, n (%, CI) 257 (43.3; 39.4–47.4)
7–9 drugs, n (%, CI) 230 (38.8; 34.9–42.8)
�10 drugs, n (%, CI) 106 (17.9; 15.0–21.2)
Physicians Characteristics (n = 117)
Age, M (SD) 52.2 (6.8)
Age Range 36–67
Gender (women), n (%) 77 (65.8)
Average length of physician career, M (SD) 18.3 (3.4)
Postgraduate Medical Education Trainers, n (%) 75 (64.1)
�O’Halloran list of Chronic Conditions for ICPC
M: Mean. SD: Standard Deviation; IQR: Interquartile Range; CI: Confidence interval
https://doi.org/10.1371/journal.pone.0237186.t001
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shows the distribution of inappropriate prescribing for each criterion. Omeprazole was the
drug that accounted for the vast majority of inappropriate prescribing, having almost one in
every five patients (19.9%) with an inappropriate MAI criterion rating. Additional information
for the most common type of drug rated inappropriate can be found in S1 Table.
Based on the updated 2014 STOPP criteria, CPAS ChecktheMeds1 detected PIP (at least
one explicit criterion) for 340 patients (57.4%), 83 more than with the 2008 version (43.3%)
(see Table 4). Eighty-two patients (13.8%) had 2 or more PIP with STOPP 2014 and 64 with
STOPP 2008 (10.8%). The most frequently found PIP was the prolonged use of benzodiaze-
pines (BZDs) for 217 patients (36.6%) using STOPP 2014 and 87 using STOPP 2008 (14.7%).
More than two out of every three study participants (68.8%) met at least one of the 2019
updated Beers criteria, twelve less than when assessing the participants with the 2015 version
(70.8%). For these patients, 197 (33.2%)had two or more PIP using Beers 2015 and 193
(30.6%) using Beers 2019. Applying the 2019 Beers criteria, the most frequent PIP was the pro-
longed used of proton-pump inhibitors (PPIs) by 260 patients (43.8%). This PIP is also the
most frequent using Beers 2015 (45.4%).
Table 2. Anatomical therapeutics classification groups of drugs prescribed.
ATC Group description N = 4,386 (%; 95% CI)
C Group Cardiovascular system 1,494 (34.1; 32.7–35.5)
A Group Metabolism and alimentary tract 952 (21.7; 20.5–23.0)
N Group Nervous system 879 (20.0; 18.9–21.3)
B Group Blood and Blood forming organs 392 (8.9; 8.1–9.8)
R Group Respiratory system 248 (5.7; 5.0–6.4)
H Group Systemic hormonal preparations, excluding sex hormones and insulins 142 (3.2; 2.8–3.9)
MGroup Musculo-skeletal system 141 (3.2; 2.7–3.9)
G Group Genito-urinary system and sex hormones 112 (2.6; 2.1–3.1)
L Group Antineoplastic and immunomodulating agents 26 (0.6; 0.4–0.9)
https://doi.org/10.1371/journal.pone.0237186.t002
Table 3. Distribution of inappropriate prescribing for each MAI criterion per drug prescribed or per patient.
Medication Appropriateness Index
Criteria
Drugs with an inappropriate MAI criterion Patients with an inappropriate MAI criterion in at least one
medication
n (%; CI 95%) n (%; CI 95%)
Indication 430 (9.8; 9.0–10.7) 285 (48.4; 44.3–52.4)
Effectiveness 724 (16.1; 15.4–17.3) 385 (65.4; 61.5–69.2)
Correct Dosage 622 (14.2; 13.2–15.2) 358 (60.8; 56.8–64.7)
Correct Directions 51 (1.2; 0.9–1.5) 46 (7.8; 5.6–10.0)
Practical Directions 553 (12.6; 11.7–13.6) 325 (55.1; 51.1–59.2)
Potentially Drug-Drug Interaction 928 (21.2; 20.0–22.4) 373 (63.3; 59.4–67.2)
Drug-Disease/Condition interaction 421 (9.6; 8.8–10.5) 178 (30.2; 26.5–34.0)
Duplication 509 (11.6; 10.7–12.6) 140 (23.8; 20.3–27.2)
Duration 775 (17.7; 16.6–18.8) 403 (68.4; 64.7–72.2)
Cost-effectiveness 979 (22.3; 21.1–23.6) 427 (72.5; 68.9–76.1)
�Medication Appropriateness Index
https://doi.org/10.1371/journal.pone.0237186.t003
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Comparisons between the implicit criteria (gold standard) and updated
explicit criteria
Table 4 shows the prevalence rates and the sensitivity and specificity for the two pair of ver-
sions of the explicit criteria comparing the old with the updated versions (STOPP 2008,
STOPP 2014, Beers 2015 and Beers 2019) and comparing all of them with the implicit MAI cri-
teria considered as the reference standard. A Venn diagram shows the agreement among the
versions (Fig 1).
For the original version of the MAI, Beers 2015 had the highest sensitivity (71.8%) to detect
PIP, followed by Beers 2019 (68.8%) and STOPP 2014 (60.1%). STOPP 2008 had the highest
specificity (82.9%). The highest positive predictive value was obtained for STOPP 2014
(97.9%). The measurements of agreement (kappa indexes) were 0.104 between STOPP 2014
and the MAI, 0.057 between STOPP 2008 and the MAI and 0.001 between Beers 2019 and the
MAI criteria.
There was no significant difference between the number of patients with PIP identified
electronically by CPAS using Beers and STOPP criteria in their two more updated versions
(p = 0.277). There were significant correlations between PIP identified by STOPP 2014 and the
MAI (r = 0.192; p<0.001), STOPP 2008 and the MAI (r = 0.185; p<0.001) and Beers 2015 and
the MAI (r = 0.311; p<0.001). The highest correlation was found between STOPP 2014 and
Table 4. Sensitivity, specificity and measurements of agreements between different implicit and explicit criteria for appropriateness prescribing evaluation.
MAI� STOPP 2014 STOP 2008 Beers 2019 Beers 2015
Prevalence of PIP (95% CI) 94.1% (92.1–96) 57.4% (53.7–61.7) 43.3% (39.6–47.7) 68.8% (65.1–72.5) 70.8% (67.3–74.6)
Sensitivity (95% CI) - 60.1% (55.9–64.2) 45.3% (41.1–49.6) 68.8% (64.7–72.6) 71.8% (67.9–75.6)
Specificity (95% CI) - 80% (63.1–91.6) 82.9% (66.4–93.4) 31.4% (16.9–49.3) 42.9% (26.3–60.6)
Positive Predictive Value (95% CI) - 97.9% (95.8–99.2) 97.7% (95–99.1) 94.1% (91.3–96.2) 95.2% (92.7–97.1)
ROC area (95% CI) - 0.7 (0.63;0.77) 0.64 (0.57;0.71) 0.5 (0.42;0.58) 0.57 (0.49;0.66)
kappa index (p-value) (95% CI) - 0.104 (0.056;0.151) 0.057 (0.025;0.089) 0.001 (-0.052;0.054) 0.052 (-0.009;0.113)
�Medication Appropriateness Index
https://doi.org/10.1371/journal.pone.0237186.t004
Fig 1. Venn diagram. Agreement among the versions.
https://doi.org/10.1371/journal.pone.0237186.g001
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Beers 2015 (r = 0.358; p<0.001) (correlation in S2 Table; the distribution of summated MAI
score per number of explicit criteria can be found in S3 Table).
Factors independently associated with inappropriate prescribing based on
implicit criteria and a comparison among explicit criteria methods
Based on the multivariable linear regression analysis for the summated MAI score, diabetes,
ischaemic heart disease and asthma were independently associated with lower summated MAI
scores (see Table 5). For every new drug taken by a patient, the MAI score increased by 2.41
(95% CI 1.46; 3.35) points. Out of all the physician factors studied, patients of doctors working
also as postgraduate medical supervisors had lower MAI scores (coef. -5.52, 95% CI -9.60;
-1.44).
Based on the multivariable logistic regressions performed for the MAI, STOPP and Beers
criteria, taking more than 10 drugs was independently associated with inappropriate prescrib-
ing according to the MAI (OR: 20.86; 95% CI: 2.09;207.78, p = 0.010), STOPP 2014 criteria
(OR: 4.96; 95% CI: 2.77;8.88, p<0.001), STOPP 2008 criteria (OR: 7.88; 95% CI: 4.48;13.8,
p<0.001) and Beers 2015 criteria (OR: 3.31; 95% CI: 1.77;6.22, p<0.001). This association was
not found for the Beers 2019 criteria. Some of the clinical conditions were found to be related
with inappropriate medication use, such as anxiety or depression, across the four main criteria
or the presence of osteoarthritis (see S4 Table). Fig 2 presents the estimated effects for different
patient and physician characteristics for the two most sensitive explicit criteria compared to
the MAI.
Discussion
Main findings
This study estimates, for the first time, the prevalence of PIP using the latest versions of explicit
internationally accepted criteria and compares it with implicit criteria (MAI). The analysis of
the criteria was performed by family doctors, with the help of a CPAS, for patients with multi-
morbidity and polypharmacy in primary care in Spain.
A total of 94.1% of the patients in this study had at least one criterion of inappropriateness
for one of their drugs according to the MAI. PIP was detected in 57.7%, 43.6%, 68.8% and 71%
of patients according to STOPP 2014, STOPP 2008, Beers 2019 and Beers 2015, respectively.
Table 5. Factors associated with summated medication appropriateness index scores.
INCREASING Coefs. CI 95% p
Number of drugs 2.41 1.46;3.35 <0.001
Usage of drugs in ATC A group (metabolism) 4.83 2.02;7.64 0.001
Usage of drugs in ATC M group (musculoskeletal) 4.81 1.85;7.77 0.002
Usage of drugs in ATC N group (nervous system) 3.31 0.87;5.74 0.008
DECREASING
Diabetes -6.29 -9.00; -3.58 <0.001
Ischaemic Heart Disease -6.92 -10.61; -3.23 <0.001
Asthma -9.13 -12.59; -5.67 <0.001
Postgraduate Medical Education Trainers -5.52 -9.60; -1.44 <0.001
PIP: Potentially inappropriate prescription; Coef: Coefficients; CI: Confidence interval
ATC: Anatomical Therapeutic Chemical classification
https://doi.org/10.1371/journal.pone.0237186.t005
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Patients with more than 10 drugs had a significantly greater presence of inappropriateness
using any of the four criteria. The MAI detected greater inappropriateness than did the explicit
criteria. Using the MAI as the gold standard, the criteria with the highest sensitivity was Beers
2015; however, the highest positive predictive value was obtained with STOPP 2014, with bet-
ter concordance measures to detect PIP compared with other versions of STOPP or Beers.
Prevalence of PIP
Implicit criteria. The prevalence of PIP varies according to the criteria used and the char-
acteristics of the population and studies [14,15,42]. The mean score of the summated MAI
score per drug was 1.4 (2.3), and the mean MAI score per patient was 17.5 (16.8). A total of
94.1% of the patients presented an inappropriate MAI criterion for a drug. These results were
similar to those reported for a study conducted in the primary care setting in the United States
with polymedicated patients aged>65 years. This study detected PIP in 98.7% of patients and a
summated MAI score per patient of 15.8 (10.1 SD) [17]. In another study in the primary care
setting in Kuwait [21], the prevalence of PIP and mean MAI score were lower (PIP in 73.6%
and MAI score per patient of 5.8 (5.8 SD)), but the population in this case had a mean con-
sumption of drugs below that in our study. In a systematic review by Patterson et al. [43] of
patients with polypharmacy aged over 65 years included in clinical trials from various areas,
this score ranged from 6.5 to 19.3 in a total of 965 participants. In the PRIMUM trial [44], with
a methodology and population similar to ours, the mean MAI was lower (4.6 (5.8 SD) in the
control group and 4.8 (5.4 SD) in the intervention group). It is possible that the way in which
the professional (pharmacist or doctor) evaluated patients with the MAI was not the same in
the studies. The results will be different when the MAI is performed together with the patient,
reviewing the clinical history (as in our study), or when only limited data are available from a
Fig 2. Estimated effects for different patient and physician characteristics for the two most sensitive explicit
criteria compared to the MAI.
https://doi.org/10.1371/journal.pone.0237186.g002
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DCN. There are some limited data regarding the summated MAI score in Spanish primary
care population. Only data from palliative care patients in Spain [45] or primary care in France
[18,46].
The most frequent MAI individual criterion found in our study also differ from those
found in the literature [17]. The item cost-effectiveness, the most frequent observed for our
patients, could be biased due to the different prices of drugs in the different regions. This item
has been eliminated in the adapted versions used in the studies that we previously indicated
[21,44]. The criterion “potential drug-drug interactions” was much more frequent in our work
than in the previous studies [21]. This difference can be related to the support tools for the
detection of interactions used by the rater. In our case, a CPAS was used that provides infor-
mation from various sources in an automated manner; this may have helped to better detect
interactions.
Language variations and different MAI-criteria weighting reduced the comparability of
these studies and can explain the differences found.
Explicit criteria. Using the Beers criteria, the prevalence was 68.8% and 70.8% for the
2019 and 2015 versions, respectively. To date, there are no data available to compare the latest
versions (2015 and 2019). For the 2015 version, the data obtained is slightly higher than those
reported by previous studies in a hospital population (53.5%) [47], and similar to studies con-
ducted with insurance databases (72.8%) [14,48]. With STOPP, this study obtained prevalence
of 57.4% and 43.6% using STOPP 2014 and 2008, respectively, which is higher than those
reported by prior studies [49,50] using previous STOPP versions in the primary care setting
and in the European population (36% and 39%, respectively). In those who used the 2014 ver-
sion, the prevalence ranged between 8.7 and 40.4% [16,41]; in a polymedicated geriatric pri-
mary care population in Kuwait, similar results were found (55.7%) [21]. The greater
prevalence observed in this study could result from the included population, which had to
meet the polypharmacy criterion to participate in the Multi-PAP trial, whereas only 72.9% or
72.1% of the patients in the abovementioned study were polymedicated.
Our results coincide with those of the majority of previous studies, placing BZDs and PPIs
among the most frequently detected PIP with explicit criteria [14–16,41,49,51]. The percentage
of patients in our sample who used BZDs for more than four weeks (STOPP v2) was similar to
that obtained by Blanco Reina [13] (36.6% vs. 38.6%). The prolonged use of PPIs was the PIP
most frequently detected in our sample, with both Beers versions (2019 (43.8%) and 2015
(45.5%)). The Beers 2015 update included this criterion, and there are already authors who
describe the prolonged use of PPIs as frequent [47], with 41.9%; however, the samples are not
comparable to ours.
Comparison between implicit criteria and explicit criteria
Taking the MAI as the gold standard, Beers 2015 had the highest sensitivity (71.8%) to detect
PIP, followed by Beers 2019 (68.8%) and STOPP 2014 (60.1%). The highest positive predictive
value was obtained using STOPP 2014 (97.9%). Our data differ from those obtained in the
Kuwait study [21] in terms of the sensitivities obtained in the explicit criteria. However, given
the characteristics of our population and the high prevalence of PIP, STOPP 2014 could have a
better diagnostic yield by having a greater positive predictive value. In other words, when
faced with a positive STOPP 2014 value, it would be more likely that PIP would actually be
confirmed by the MAI in patients with multimorbidity and polypharmacy. This is especially
relevant in populations with a priori suspicion of a high prevalence of inappropriateness. This
differs from similar studies in which the median number of drugs was lower and the popula-
tion was different [21].
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In Steinman’s study they found that patients with a MAI score of three or more points on
any drug had a Beers criterion of 34%. In hospitalized patients, those with a Beers criterion at
admission had a mean of 7.17 (0.11–14.23) summated-MAI score [52].
We obtained a higher prevalence of PIP with the MAI. These implicit criteria are potentially
the most sensitive ones and can take into account patients’ preferences. However, these meth-
ods are time-consuming and it requires intensive training and extensive knowledge [8,20].
This means that they may not be the first option in clinical settings. Other tools, such as com-
puter-automated explicit criteria, may be better options as an initial approach to determining
the risk of drug inappropriateness.
It is evident that the common use measures of the quality of prescriptions produce widely
discordant results (different quality metrics measuring different constructs). In studies com-
paring explicit methods with each other, the concordance among methods was low [16,51,53].
The different tools available can be complementary, and the decision to use one or the other
should be related to the setting in which it is used and the purpose of its use. In research set-
tings, a robust evaluation of the quality of prescriptions is probably necessary. However, in
clinical practice, the use of explicit criteria, with less clinical detail and more easily automat-
able, can be applied more easily and quickly.
Factors associated with PIP
In this study, we found that diseases such as diabetes, ischaemic heart disease and asthma were
significantly associated with a lower summated MAI score. It is possible that patients with
these pathologies, which are well defined and delimited, with frequent and protocolled visits,
are subjected to more follow-ups at which there is opportunity to properly review medication
and to easily detect situations of drug inappropriateness. Patients of doctors working both, as
family physicians and postgraduate medical supervisors, had lower summated MAI score. We
have not found other studies that have reported similar results. This could be related to the
greater training required for those working as supervisors and also because of increased aware-
ness in terms of reviewing treatments for polymedicated patients. Additionally, there is a clear
association between a greater number of drugs and the summated MAI score. Taking more
than 10 drugs is associated independently with greater detection of PIP with explicit criteria
and with the MAI. This result continues to make the cut-off of 10 drugs a possible proxy for
complex multimorbidity and an important indicator of risk.
Conclusion
In conclusion, the prevalence of PIP detected in the sample was high and in agreement with
previous literature in young senior population with multimorbidity and polypharmacy. The
MAI criteria detected greater inappropriateness than did the explicit criteria, but their applica-
tion was more complex and difficult to automate.
Future studies should evaluate whether the application of implicit and explicit criteria with
the help of automated tools by a professional alone, among others, could change the usual clin-
ical practice and improve patient health.
Strengths and limitations
We found that this study covers an objective for which it was not initially designed. There was
an attempt to partially correct this fact by estimating the aforementioned power as well as esti-
mating the intervals with robust estimators to control the randomness introduced by the type
of sampling. However, although the baseline information is trustworthy and was collected by
each patient’s doctor and verified, the MAI evaluation, which was performed by another
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external physician, was not performed with the patient in an interview but rather by reviewing
each patient’s medical history, which may have resulted in an inappropriate valuation of some
criteria related to the perspectives of the patient and the prescribing physician that may not be
included in medical records.
Among the strengths, it is noteworthy that this is the first Spanish study that automatically
evaluated PIP with Beers 2019. It is also the first one comparing explicit and implicit criteria in
its latest versions with the MAI. In addition, data collection through an interview with each
patient’s own doctor, the pragmatic design and an exhaustive review of each patient’s clinical
history by the raters confer reliability to the data in this work.
Future studies should evaluate whether the application of implicit and explicit criteria with
the help of automated tools by a professional alone, among others, could change the usual clin-
ical practice and improve patient health.
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